778 related articles for article (PubMed ID: 22212151)
21. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
24. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
[TBL] [Abstract][Full Text] [Related]
25. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
Campochiaro PA; Sophie R; Pearlman J; Brown DM; Boyer DS; Heier JS; Marcus DM; Feiner L; Patel A;
Ophthalmology; 2014 Jan; 121(1):209-219. PubMed ID: 24112944
[TBL] [Abstract][Full Text] [Related]
27. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833
[TBL] [Abstract][Full Text] [Related]
29. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
[TBL] [Abstract][Full Text] [Related]
30. Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis).
Karagiannis DA; Karampelas MD; Soumplis VM; Amariotakis C; Georgalas I; Kandarakis A
Can J Ophthalmol; 2011 Dec; 46(6):486-90. PubMed ID: 22153634
[TBL] [Abstract][Full Text] [Related]
31. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
[TBL] [Abstract][Full Text] [Related]
32. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
Thach AB; Yau L; Hoang C; Tuomi L
Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
[TBL] [Abstract][Full Text] [Related]
33. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
Niederhauser N; Valmaggia C
Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
[TBL] [Abstract][Full Text] [Related]
34. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
37. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.
Kriechbaum K; Michels S; Prager F; Georgopoulos M; Funk M; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Apr; 92(4):518-22. PubMed ID: 18211942
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
[TBL] [Abstract][Full Text] [Related]
40. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion.
Kang JW; Lee H; Chung H; Kim HC
Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1413-21. PubMed ID: 24577742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]